Compounded vs Brand-Name GLP-1 Medications: The Honest Trade-Off Guide

The first thing most people do after getting a semaglutide or tirzepatide prescription is check the price. And the number that comes back — $1,000 or more per month for Wegovy, $550–$650 for Zepbound — sends a large portion of them straight to Google looking for alternatives.

Compounded versions of these drugs exist. They're cheaper, often dramatically so. And they come with real trade-offs that aren't always clearly explained on the telehealth platforms selling them.

This isn't a scare piece about compounded medications — some people have genuinely good reasons to use them, and legitimate compounding pharmacies exist. But the differences between compounded and brand-name GLP-1s are specific enough that they deserve a clear-eyed breakdown. We've gone through the FDA guidance, the cost data, and the regulatory context so you have the full picture before making the call.

What "Brand-Name" Actually Means Here

Brand-name GLP-1s are manufactured by the originating pharmaceutical companies — Novo Nordisk for semaglutide (Ozempic, Wegovy, Rybelsus) and Eli Lilly for tirzepatide (Mounjaro, Zepbound).

"FDA-approved" in this context means the active ingredient, formulation, manufacturing process, and labeling have all been reviewed and cleared through the FDA's new drug application process.

The clinical trials that generated the efficacy data — STEP 1 for Wegovy, SURMOUNT-1 for Zepbound — were conducted using these specific formulations. When you're on Wegovy, you're on the molecule whose 15% average weight loss was established in those trials.

The brand-name drugs also come in validated delivery devices — prefilled autoinjector pens with calibrated doses. That matters more than it sounds: semaglutide and tirzepatide are both dosed in fractions of milligrams, and small dosing errors at those scales have real consequences.

Current brand-name costs:

• Wegovy (semaglutide): ~$1,000/month retail; some insurance coverage available; Novo Nordisk savings programs available for qualifying patients
• Zepbound (tirzepatide): ~$550–$650/month retail; LillyDirect self-pay option from $299–$449/month depending on dose
• Ozempic and Mounjaro (diabetes-indicated versions): frequently covered by insurance for patients with type 2 diabetes

What "Compounded" Actually Means Here

Compounding is the practice of a licensed pharmacy preparing a customized medication — mixing, combining, or altering ingredients to meet a specific patient need. It's been legal for over a century and serves genuinely useful purposes: removing an allergen, creating a liquid form for someone who can't swallow pills, or providing a drug that's temporarily in shortage.

GLP-1 compounding became widespread during the semaglutide shortage period that began around 2022. The FDA allows compounding of FDA-approved drugs that are on the shortage list from specific types of compounding pharmacies — 503A (patient-specific) and 503B (large-scale outsourcing facilities).

Compound pharmacies sourced the active ingredient in powder or API form and produced injectable versions of semaglutide and tirzepatide at dramatically lower prices.

Current compounded costs (approximate):

• Compounded semaglutide: $130–$300/month
• Compounded tirzepatide: $200–$400/month

That's a real gap. At $196/month for compounded semaglutide versus $1,000/month for Wegovy, the annual difference is roughly $9,600. For most people, that's not a trivial number.

The Safety Question — What the FDA Has Actually Said

This is where the compounding conversation gets more complicated than most telehealth platforms acknowledge.

The FDA's stance on compounded GLP-1s shifted materially in 2025, when the agency removed semaglutide and tirzepatide from the shortage list. Once a drug is no longer in shortage, the legal basis for widespread compounding largely disappears. 503B outsourcing facilities — the larger compounding operations that supplied most of the telehealth market — are no longer authorized to produce these drugs at scale.

503A pharmacies (patient-specific) can still compound in some circumstances, but only for individual patients with a documented clinical need that the brand-name product can't meet — not as a general price-access alternative.

The adverse event data is worth knowing. An analysis through 2025 found over 1,000 adverse event reports linked to compounded semaglutide and tirzepatide, including hospitalizations.

That doesn't mean compounding is categorically dangerous — adverse events get reported at higher rates for newer, high-profile medications. But it does point to real risks in a supply chain with less standardization than brand-name manufacturing.

The most specific FDA language concerns retatrutide. The agency has issued warning letters describing compounded retatrutide as an unapproved new drug — not a compounded version of an approved product, but an entirely illegal category.

Retatrutide isn't FDA-approved at all, so there's no legal basis for compounding it whatsoever. If you see it offered anywhere, walk away. We cover the full retatrutide picture in our retatrutide explainer.

What Changes — and What Doesn't

The practical differences between brand-name and compounded GLP-1s come down to four things: manufacturing certainty, delivery format, cost, and current legal standing.

What changes with brand-name:

The active ingredient is the same molecule that appeared in the clinical trials. Manufacturing is standardized across batches — you know the dose you're drawing is the dose on the label. The prefilled pen makes administration straightforward, with less room for self-dosing error than drawing from a vial with a syringe. And the legal situation is unambiguous.

What changes with compounded:

Cost drops by 30–80%. Access through telehealth is faster, often without the multi-step prior authorization process that brand-name GLP-1s require. But potency can vary between pharmacy batches, vial-and-syringe dosing adds a user-error variable, and the legal framework post-shortage has tightened enough that ongoing supply from telehealth providers is less certain than it was in 2023–2024.

What doesn't change either way:

The mechanism of action is identical — you're getting the same molecule acting on the same receptors. Weight loss outcomes in clinical practice, as opposed to controlled trials, depend heavily on adherence, starting weight, diet quality, and activity.

Neither version is going to produce better results if protein intake isn't managed, resistance training isn't in place, or micronutrient gaps aren't addressed.

That last point is important enough to be explicit: the nutrient depletion that comes with eating 30–40% less doesn't care about what brand is in the syringe.

The Pros and Cons, Side by Side

Who Should Choose What

The Supplement Side — What Doesn't Change

This is the part of the conversation that rarely comes up on telehealth platforms, but it matters regardless of which version of the drug you're on.

GLP-1 medications work by suppressing appetite enough to significantly reduce calorie intake. That reduction — typically 16–40% less food — creates nutrient gaps that aren't resolved by the drug itself. Protein, vitamin B12, vitamin D, iron, magnesium, and fat-soluble vitamins all tend to drop when food volume drops.

Muscle loss is the most clinically documented concern. About 25–33% of total weight lost on GLP-1 therapy comes from lean tissue rather than fat.

Protein at 1.2–2.0g per kilogram of body weight daily is the primary tool for narrowing that ratio. Resistance training 2–3 times per week signals the body to preserve muscle even in a deficit. Creatine monohydrate at 5g daily has direct clinical support for maintaining strength and lean mass during caloric restriction.

None of that changes based on what brand is in the syringe. Our best supplements for GLP-1 users guide covers the full stack with specific product picks. If GI side effects are your bigger concern — nausea and constipation hit a majority of users during dose escalation — we break down what the evidence supports in our GLP-1 side effects guide.

For context on the three drug generations — semaglutide, tirzepatide, and the investigational retatrutide — and how their efficacy data compares, see our three-generation peptide comparison.

Talk to the prescriber who knows your full health history before choosing either route. That's the one piece of advice that applies to everyone regardless of budget.